|
Principal and Member, Burrill Investment Committee. Since 1998, Mr. Fong has been focused on sourcing, evaluating and investing in biotechnology companies through the Burrill Life Sciences Capital Funds, which combined total almost $1 billion for investments in the life sciences. He has been involved in over twenty-five venture capital financings including recent investments in Galapagos (GLPG), SCYNEXIS, Catalyst Biosciences, Alinea Pharmaceuticals, Pharmasset (VRUS), Elbion, Neurotech Pharmaceuticals, Logical Therapeutics, and TRF Pharma. In addition to serving on Odyssey Thera's board of directors, Mr. Fong currently serves on the boards of directors for Neurotech Pharmaceuticals, TRF Pharma, Logical Therapeutics (observer), Elbion (observer), and Phytomedics (observer). Prior to joining Burrill & Company, Mr. Fong held positions as a biochemist and molecular biologist with two early stage biotechnology companies located in the San Francisco Bay Area. Mr. Fong's aggregate research experiences include recombinant protein expression in yeast, development of linear artificial chromosomes, and catalytic RNA technology. Mr. Fong earned his bachelors degree with distinction and honors in Molecular and Cell Biology-Biochemistry from the University of California, Berkeley. | 